27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Dynavax Technologies Corp (NASDAQ:DVAX) shares are trading higher on Tuesday, after the company said it intends to provide an update on early-stage coronavirus vaccine candidate collaborations. The company expects at least one of its collaborators to commence a Phase 1 clinical trial of a potential vaccine as early as July.
Dynavax Technologies is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Dynavax shares were trading up 22.74% at $5.96 on Tuesday. The stock has a 52-week range between $7.20 and $1.80.
Related Links:
Moderna To Raise $1.3B In A Public Offering As Coronavirus Vaccine Trials See Progress
Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!